SequelSEC

iBio, Inc. IBIO

Pharmaceutical Preparations · CIK 0001420720 · Fiscal year ends 0630

Revenue
$100.00K
Fiscal year ended 2026-06-30
Operating income
-$35.14M
Fiscal year ended 2026-06-30
Free cash flow
-$23.80M
Fiscal year ended 2026-06-30

iBio, Inc. (IBIO) reported revenue of $100.00K and net income of -$33.04M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from iBio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

iBio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Revenue$100.00K$400.00K$225.00K$0$1.88M$2.37M$1.64M$2.02M$444.00K$394.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable$1.46M$703.00KUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable$909.00K$935.00KUnavailableUnavailableUnavailable
Operating income-$35.14M-$18.60M-$16.63M-$29.34M-$29.70M-$31.11M-$14.00M-$15.79M-$14.23M-$14.27M
Net income-$33.04M-$18.38M-$24.91M-$65.01M-$50.30M-$23.21M-$16.44M-$17.59M-$16.10M-$14.53M
Research & development$19.64M$8.31M$5.18M$10.33M$9.83M$9.99M$3.57M$5.47M$3.99M$4.12M
Weighted-average diluted sharesshares 104.06Mshares 10.50Mshares 3.83MUnavailableshares 8.72Mshares 7.82MUnavailableUnavailableUnavailableUnavailable
Pretax income-$33.04M-$18.38MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPS$-0.32$-1.75$-6.50$-106.19$-5.78$-3.00UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$10.60M$10.69M$11.67M$19.02M$21.75M$22.03M$11.36M$12.33M$10.68M$10.55M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

iBio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Cash & equivalents$56.40M$8.58M$14.21M$4.30M$22.68M$77.40M$55.11M$4.42M$4.42M$15.93M
Total assets$99.11M$23.18M$28.73M$41.21M$99.41M$146.97M$94.19M$30.59M$43.08M$36.01M
Current assets$92.22M$9.72M$15.67M$26.26M$45.07M$104.60M$61.75M$4.81M$16.28M$8.57M
Total liabilities$13.40M$8.30M$7.41M$25.83M$35.92M$38.40M$37.58M$28.13M$26.92M$27.10M
Current liabilities$11.74M$6.11M$3.84M$22.11M$30.44M$6.64M$5.24M$3.46M$2.04M$2.01M
Total equity incl. NCI$85.71M$14.88M$21.32M$15.38M$63.48M$108.57M$56.61M$2.46M$16.16M$8.92M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailable$0$0$3.90M$27.00KUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailable$0$0$1.00M$426.00K$75.00K$97.00K$75.00K$175.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$4.42M$2.19M$358.00K$1.85M$4.26M$2.25M$1.76M$1.00M$790.00K$749.00K

Cash flow

iBio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Operating cash flow-$23.22M-$15.30M-$18.55M-$30.44M-$37.48M-$30.06M-$13.34M-$13.98M-$13.48M-$13.16M
Capital expenditures$578.00K$16.00K$210.00K$5.74M$7.33M$4.92M$1.08M$920.00K$934.00K$1.32M
Investing cash flow-$32.00M$742.00K$906.00K$7.01M-$5.13M-$26.48M-$1.15M-$990.00K-$1.08M-$1.59M
Financing cash flow$103.05M$8.93M$24.49M$2.30M-$6.12M$78.84M$65.19M$3.45M$22.41M-$170.00K
Net change in cash$47.83M-$5.63M$6.85M-$21.09M-$48.73M$22.29M$50.69M-$11.51M$7.85M-$14.93M
Stock-based compensation$1.37M$1.53M$2.04M$4.39M$4.38M$1.59M$388.00K$241.00K$770.00K$1.01M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$179.00KUnavailableUnavailable

Derived

iBio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Free cash flow-$23.80M-$15.32M-$18.76M-$36.17M-$44.81M-$34.98M-$14.42M-$14.90M-$14.41M-$14.49M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable38.3%57.1%UnavailableUnavailableUnavailable
Operating margin-35141.0%-4650.5%-7392.9%Unavailable-1576.3%-1312.1%-854.9%-782.4%-3204.3%-3622.8%
FCF margin-23796.0%-3830.0%-8339.6%Unavailable-2378.5%-1475.5%-880.5%-738.1%-3246.4%-3676.6%
SBC / revenue1373.0%382.5%905.8%Unavailable232.3%66.9%23.7%11.9%173.4%256.3%
Current ratio7.85x1.59x4.08x1.19x1.48x15.74x11.79x1.39x8.00x4.26x
Revenue YoY growth-75.0%77.8%Unavailable-100.0%-20.5%44.7%-18.8%354.5%12.7%Unavailable
Net margin-33044.0%-4594.2%-11069.8%UnavailableUnavailable-978.8%-1003.6%-871.8%-3627.3%-3688.3%
R&D / revenue19643.0%2078.0%2304.4%Unavailable521.6%421.3%218.1%271.3%897.7%1044.9%
CapEx / revenue578.0%4.0%93.3%Unavailable389.1%207.5%65.8%45.6%210.4%335.8%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IBIO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-08-28View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-Q · Filed 2026-02-10View SEC filing
10-Q/A · Filed 2025-11-17View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-K · Filed 2025-09-05View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2022-06-30

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.